This is your chance to invest in next-generation therapeutics for cancer and autoimmune disease that build on the groundbreaking work of two Lasker Award-winning scientists.
Antibodies and cells

Company Highlights

Enosi (from Greek ‘enosis’ meaning combination) was formed by Professor Sir Marc Feldmann and Dr. H. Michael Shepard to combine technologies from cancer and autoimmune disease research to create novel and more effective drugs for each disease.

  • Dr. Feldmann:  Best known for inventing TNF Blockers (~$40B/year industry)
  • Dr. Shepard: Best known for the trastuzumab/Herceptin franchise of Genentech/Roche (~$10B/year).
  • Both are recipients of the Albert and Mary Lasker Award for Clinical Research

These industry-leading experts will combine their talents, networks and experience to address the growing global health challenges of autoimmune diseases, cancer and acute inflammatory conditions.

Lasker Foundation
Enosi Life Sciences 506(c) Offering
Enosi Life Sciences Corp.
$8.00 per share
Open to accredited investors in accordance with Reg. D 506(c)

View Enosi Life Sciences’ official Form D as filed with the United States Securities and Exchange Commission (SEC)

Corporate Presentation

Learn about Enosi Life Sciences’ mission, founders, and exciting new scientific research targets for next-generation treatments of cancer and autoimmune diseases.

Research TargetS

All TNF blockers and JAK inhibitors have black box warnings related to opportunistic infections, cancer and now cardiovascular events. New drugs with a different mechanism of action are needed to address these problems.

The company is focusing its attention on two projects that are new to treatment of rheumatoid arthritis and other autoimmune disease.

The first project is a specific inhibitor of TNFR1 (EN1001) and the second is a growth factor trap that inactivates inflammatory growth factors which otherwise would induce proliferation of cells that produce TNF in the synovial joints of rheumatoid arthritis patients (EN2001).

Both are new chemical entities that work by novel mechanisms of action and are covered by Enosi’s patent filings. Both programs have precursor molecules with existing in vitro and in vivo proof of concept in animal models of rheumatoid arthritis (RA). EN2001 precursor molecule also has activity in vitro and in vivo in cancer models.

Two other programs are anticipated when funding allows. The first is an anti-TNFR2 program (two products), and the second is an innovative multi-specific antibody-like drug and targeting platform.

About Enosi Life Sciences

January 2020 (Delaware)
San Diego, CA

Market Opportunity

Total Addressable Market: $346.6+ billion by 2026
Cancer and autoimmune therapy markets are huge—and growing

The global cancer immunotherapy market is expected to grow at a CAGR of around 10.6% from 2019 to 2026 and expected to reach the market value of around US$ 115.4 Bn by 2026

Monoclonal antibody market
  • $125b in 2020
  • Projected to reach over $148.9B by 2026 (Source)
  • $40b+ TNF Inhibitors
  • Projected to be $42.1b by 2026 (Source)
Potential Other MAb TNF Inhibitor Markets for Enosi Molecules
  • Organ Transplant/Rejection Inhibitors: $18.21b by 2023 (Source)
  • Alzheimer’s: $10.5b by 2025 (Source)
  • Parkinson’s: $8.3b by 2026 (Source)
  • Acute Respiratory Distress Syndrome (ARDS): $990.88m by 2027
  • Cachexia (as related to cancer and geriatric population): $2.2b by 2024

Competitive AdvantageS

Acknowledged research/content experts
  • Feldmann and Shepard have both drug discovery and drug development successes.
  • Feldmann discovered TNF Blockers for autoimmune disease (~40B/y).
  • Shepard discovered trastuzumab (Herceptin)
  • Trastuzumab and its franchise are worth about $10B/y
  • Shepard headed up discovery programs at Canji/Schering Plough (gene therapy), NewBiotics (small molecule prodrugs), Receptor Biologics (dominant negative soluble receptors), and Halozyme (drug delivery and cancer therapeutics).
Experience & Networks
  • Proven experience in developing, marketing, and commercializing drugs
  • Demonstrated proficiency
  • Reduced costs by outsourcing non-IP-related operations
  • Substantial biotech/pharma, institutional investor, regulatory, academic, etc., network
  • Cost-effective and efficient preclinical and clinical development by leveraging academic resources
Two Patents Filed
  • PCT International Application Number PCT/US2020/018739: Filed February 19, 2020
  • Provisional Patent: Filed August 28, 2020
  • These cover Enosi’s technology, compositions of matter, and methods of use.

Timelines to Phase I/II CLINICAL TRIALS


Enosi Life Sciences founded

Dr. H. Michael Shepard and Professor Sir Marc Feldmann join forces

3-4 years

EN1001 – Anti-TNFR1

4 years

EN2001 – Growth Factor Trap for RA

Sir Marc Feldmann

Sir Marc Feldmann, M.D. Ph.D.

Director & Co-founder

  • Sir Marc Feldmann is a preeminent immunologist, and an Emeritus Professor at the University of Oxford.
  • With Sir Ravinder Maini, identified TNF as a target. Trials of Infliximab (Remicade) they led were successful, and prompted J&J’s $4.9B USD acquisition of Centocor.
  • Anti-TNF sales > $50B USD globally.
  • Professor Sir Marc Feldmann is a Fellow of the Royal Society , of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent.
  • He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, the Ernst Schering Award.
Dr. H. Michael Shepard

H. Michael Shepard, Ph.D.

CEO & Co-founder

  • Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics.
  • Best known for his invention of “Herceptin”/Trastuzumab, which has remained one of the most profitable platforms for Roche (>$7B USD).
  • Dr. Shepard is a highly-experienced and respected leader with many successful ventures in this field – working at Genentech (sold to Roche – $46.8 B USD), Canji, Inc. (bought by Scheirng-Plough) and Halozyme (now valued at $2.6B USD).
  • Widely acknowledged biomarker pioneer and recognized worldwide, Dr. Shepard has received the 2019 Albert Lasker Award and the Warren Alpert Prize, among many other professional accolades.

James N. Woody

James N. Woody

Executive Chairman

  • Jim brings more than 25 years of pharmaceutical research and management experience to Enosi.
  • In addition to his duties as a consultant to LVP, where he served as a General Partner for 14 years, Jim is currently Chairman of Viracta Therapeutics, a company focusing on unique therapies for virally induced cancers.  
  • He was the founding CEO of OncoMed Pharmaceuticals, a cancer therapeutic antibody company. He was the Board member for both ForteBio, and Protein Simple, both successfully acquired. Jim was formerly President and GM of Roche Bioscience (former Syntex) in Palo Alto, CA. 
  • Previously, Jim served as Chief Scientific Officer and Senior Vice President of R&D for Centocor. While at Centocor, Jim’s team developed the blockbuster drug Remicade. 
  • Jim served as a Navy Medical Officer, and was Head of the Navy Transplant Research Program. With his colleagues and with both Navy and Congressional support, founded the National Marrow Donor Program. 
  • He was promoted to Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War and was awarded the Marine Corps/US Navy Legion of Merit for his service. 
  • Jim served as Chairman of the Silicon Valley Leadership Group representing over 120 Silicon Valley Companies, is a board member of the Lucile Packard Children’s Hospital (Stanford).
  • Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. He was Professor of Pediatrics and Microbiology at Georgetown University School of Medicine 1982-1996. He has authored or co-authored over 140 publications.